Abstract: Provided herein are methods of treating cancer in a subject with a ZIP9 inhibitor. In certain embodiments, the cancerous tissues do not express the nuclear androgen receptor (AR). These methods, alone or in combination with other cancer therapies, can improve treatment outcomes in patients suffering from cancer, particularly male patients.

Abstract: Provided herein are methods of treating cancer in a subject with a ZIP9 inhibitor. In certain embodiments, the cancerous tissues do not express the nuclear androgen receptor (AR). These methods, alone or in combination with other cancer therapies, can improve treatment outcomes in patients suffering from cancer, particularly male patients.

Abstract: The present invention relates to the use of apolipoprotein A, a mimetic peptide thereof, or an activator thereof for the preparation of a medicinal product for the treatment or prevention of cancer. The invention also relates to a method for determining the stage of a colorectal tumor in a patient, where the method comprises determining ApoA1 levels in a biofluid from said patient, wherein decreased ApoA1 levels with respect to a reference value indicate a more advanced stage of the tumor, as well as a method for selecting treatment for a cancer patient, where the method comprises determining ApoA1 levels in a biofluid from said patients, wherein decreased ApoA1 levels with respect to a reference value indicate that the therapy of choice is a therapy based on apolipoprotein A, a mimetic peptide thereof, or an activator thereof.